BrainStorm hires PharmaNet to get FDA ALS clinical trial approval
This article was originally published in Scrip
Executive Summary
The CRO PharmaNet is to help BrainStorm Cell Therapeutics, a developer of adult stem cell technologies and CNS therapeutics, to develop the protocol and IND file for submission to the US FDA for approval to conduct amyotrophic lateral sclerosis (ALS) clinical trials in the US.